The historical rank and industry rank for Helius Medical Technologies's Price-to-Free-Cash-Flow or its related term are showing as below:
HSDT's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.9 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 67.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 61.00% per year.
During the past 10 years, Helius Medical Technologies's highest 3-Year average Free Cash Flow per Share Growth Rate was 67.30% per year. The lowest was -228.90% per year. And the median was 34.80% per year.
Helius Medical Technologies Price-to-Free-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Helius Medical Technologies Price-to-Free-Cash-Flow Chart
Competitive Comparison of Helius Medical Technologies's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, Helius Medical Technologies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helius Medical Technologies's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Helius Medical Technologies's Price-to-Free-Cash-Flow falls into.
Helius Medical Technologies Price-to-Free-Cash-Flow Calculation
Helius Medical Technologies's Share Price of today is $0.579. Helius Medical Technologies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Helius Medical Technologies (NAS:HSDT) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Helius Medical Technologies Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Helius Medical Technologies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSDT has been successfully added to your 